MY01 Welcomes Joe Kiani as Investor and Board Member
MY01, a pioneering medical technology company specializing in limb perfusion injury diagnostics, has announced an exciting new development. Joe Kiani, recognized globally for his contributions to medical innovation and as the founder of Masimo, has invested in MY01 and will be joining their Board of Directors.
A New Chapter in Patient Monitoring
Charles Allan, CEO of MY01, expressed enthusiasm about Kiani's involvement, stating, "We are excited to welcome Joe Kiani as an investor and board member at MY01. His impressive background in innovating patient monitoring technologies and dedication to enhancing patient lives perfectly aligns with our mission." Together, Kiani and MY01 aim to push the boundaries of limb health with their groundbreaking continuous perfusion sensing technology (CPST).
Transforming Healthcare Delivery
Kiani's reputation stems from his founding of Masimo, a leader in medical technology known for its revolutionary non-invasive monitoring solutions like pulse oximetry. These innovations have redefined care delivery and significantly improved patient outcomes, saving countless lives. In addition to his work with Masimo, he established the Patient Safety Movement Foundation, advocating for the elimination of preventable healthcare deaths.
Building on a Vision of Innovation
Kiani highlighted the significance of MY01's CPST platform, noting, "MY01's breakthrough CPST platform has been shown to help clinicians save limbs and lives by detecting lack of limb perfusion after an injury. Over one million limb injuries occur annually, and without this technology, clinicians face challenging decisions with limited data. CPST is indeed a game changer." His commitment to supporting MY01 reflects a shared vision to improve patient lives globally.
Advancements in Trauma Care
This strategic investment in MY01 allows the company to further develop its CPST platform, which is designed to minimize variations in orthopedic and vascular trauma care. Additionally, MY01 is set to lead advancements in cardiogenic shock monitoring, providing healthcare professionals with tools to enhance outcomes for critically ill patients.
About MY01
Founded in 2019, MY01 seeks to create a future where all diseases can be quantitatively assessed, resulting in tailored care for every patient. The company's CPST platform is transforming trauma care by turning complex biological data into immediate, actionable insights. This innovative approach not only decreases care variability but also aids hospitals in optimizing resource allocation. MY01 is actively changing the healthcare landscape in multiple regions, including the USA, Europe, and Canada.
Media Inquiries
For further information, please contact Interdependence Public Relations at (949) 777-2468.
Frequently Asked Questions
Who is Joe Kiani?
Joe Kiani is the founder of Masimo, known for his groundbreaking work in medical technology and his new role at MY01 as an investor and board member.
What is the CPST platform?
The Continuous Perfusion Sensing Technology (CPST) platform developed by MY01 helps detect perfusion issues in limbs, aiding in timely medical intervention.
How will Joe Kiani's involvement benefit MY01?
Kiani's extensive experience and innovation in patient monitoring will enhance MY01's capabilities and drive forward its mission of improving healthcare delivery.
When was MY01 founded?
MY01 was founded in 2019 with the aim of revolutionizing how diseases are monitored and treated, providing personalized care solutions.
Where is MY01 operational?
MY01 operates in the USA, Europe, and Canada, aiming to set new standards in healthcare practices globally.
